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Abstract

The killing activity of daptomycin against an isogenic pair of daptomycin-susceptible and daptomycinnonsusceptible (DNS) methicillin-resistant Staphylococcus aureus (MRSA) strains was enhanced by the
addition of certain cell wall agents at 1× MIC. However, when high inocula of the DNS strain were used, no
significant killing was observed in our experiments. Cytochrome c binding assays revealed d-cycloserine as the
only agent associated with a reduction in the cell surface charge for both strains at the concentrations used.
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Abstract:
The killing activity of daptomycin against an isogenic pair of daptomycin susceptible and
daptomycin non-susceptible (DNS) MRSA strains was enhanced by the addition of
certain cell wall agents at 1xMIC concentrations. However, when high inocula of DNS
were used, no significant killing was observed in our experiments. Cytochrome c binding
assays revealed D-cycloserine as the only agent associated with a reduction in the cell
surface charge of both strains, at the concentrations used.

2

Manuscript
The mechanisms of resistance to daptomycin in Staphylococcus aureus have been related
to cell membrane alterations; cell wall thickening, modifications in membrane lipid
composition, altered drug binding and changes in the surface charge (1).
Almost all synthesis of (the positively charged) D-alanine in S. aureus is controlled by
alanine racemase (2,3). D-cycloserine (DCS) is a D-alanine analog used as a second-line
treatment for mycobacterial infections. It prevents peptidoglycan synthesis in bacterial
cell wall by a competitive inhibition of both alanine racemase and D-alanine ligase
enzymes (4,5)
The aim of this study was to ascertain the effect of DCS, in comparison to other cell wall
agents (CWA), on the activity of daptomycin against MRSA and to assess related
variations in cell surface charge. For this purpose, an isogenic pair of MRSA strains from
an episode of bacteremia and osteomyelitis treated with daptomycin was used: the
daptomycin-susceptible progenitor, A8796 (DS) and the daptomycin-non susceptible
derivative, A8799 (DNS), which harbored an mprF mutation (S337L) (6).
Daptomycin (Cubist Pharmaceuticals, Inc, Lexington, MA) and CWA were used in this
study: vancomycin (VAN), ampicillin (AMP), oxacillin (OXA), cefazolin (CFZ),
imipenem (IMI), fosfomycin (FOM) and D-cycloserine (DCS) (Sigma-Aldrich
Corporation, St.Louis MO). For all experiments the purified powder of each antibiotic
was resuspended following the CLSI recommendations (7).
Determination of Minimum inhibitory concentrations (MICs) and studies of
daptomycin susceptibility. MICs of daptomycin, DCS and FOM were determined by
broth macrodilution method according to standard recommendations (7). MICs of all
other antibiotics were determined by the E-test (AB BioMerieux, Solna, Sweden),
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according to the manufacturer’s instructions (Table 1). A see-saw effect (8,9) between the
DAP MIC (increased) and the MICs of beta-lactams (decreased) was observed for the
isogenic isolates (Table 1). Although this phenomenon is not completely understood, it
might be related to an alteration of mecA gene regulation in the DNS isolates (9).
48-hour time-kill curves (TKC) were performed following standard methodology (10).
Standard inoculum (106CFU/ml) and high inoculum (108CFU/ml) of bacteria were used.
In order to mimic clinically-relevant serum concentrations, 8 µg/mL (D8) of DAP were
used in all experiments (11), either alone or in combination with CWA at prefixed
concentrations of 1xMIC. Daptomycin alone and all the CWA showed no net killing
activity at 48 hours against both strains. Against standard inoculum DS the addition of all
CWA to DAP produced greater killing compared to D8 alone, but bactericidal activity
was only maintained at 48h with the combinations OXA+D8 (Δ-3.93log), DCS+D8 (Δ3.85log) and CFZ+D8 (Δ-3.17log). Bacterial regrowth at 48 hours was only prevented by
the combinations DCS+D8 and OXA+D8 (Figure 1A). Against high inoculum DS
bactericidal activity at 24h was only maintained at 48h with the combinations OXA+D8
(Δ-4.73log), DCS+D8 (Δ-5.85log) and IMI+D8 (Δ-4.64log) but regrowth was only
prevented by the combination DCS+D8 (Figure 1B). Against standard inoculum DNS,
the only combinations that prevented regrowth at 48 hours were OXA+D8 (Δ-3.80log),
IMI+D8 (Δ-3.66log) and DCS+D8 (Δ-3.77log) (Figure 1C). As shown in figure 1D,
against high inoculum DNS, synergy was not observed with any combination. In
summary, at the concentrations used OXA, DCS and IMI had a comparable effect on
daptomycin killing, there being synergistic or additive activity with D8 in three of the
experiments (with the exception of DNS at initial high inoculum). However, DCS+D8
did not allow regrowth at 48 hours in any of those three experiments, and was the only
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combination achieving net killing against the DNS strain at initial high inoculum (Δ0.48log). As far as we know, this is the first time that DCS+daptomycin activity has been
tested against MRSA. Synergism between daptomycin and beta-lactams or fosfomycin
has been previously observed (12-15) and is further supported from our experiments.
Evaluation of bacterial surface charge (16). After overnight growth in trypticase soy
broth (TSB), cultures were resuspended in fresh medium containing one CWA at 1xMIC.
It was then resuspended in fresh medium containing the positively charged molecule
cytochrome c (CyC) from bovine heart (Sigma). The optical density (A405) of the
supernatant was measured (SPECTRAmax Plus 384, Molecular Devices Corporation,
Sunnyvale, CA) and the total amount of cell-bound CyC was obtained using a standard
curve. Experiments were repeated 4 times. Analysis of variance test with the post hoc
Bonferroni correction were used to determine differences in the bound CyC means in the
presence of various antibiotics. Differences were considered statistically significant when
P values were ≤0.05. In the absence of antibiotic exposure, significant differences
(p<0.05) were found between the amount of CyC bound to A8796 (1.39mg+ 0.07) and
A8799 (1.22mg+0.09) (Figures 2A and 2B). For both strains, the amount of CyC bound
in the presence of DCS at 1xMIC was significantly higher compared to that bound in its
absence (1.26-fold increase for A8796 and 1.68-fold increase for A8799). We
hypothesize that the reduction in D-alanine synthesis achieved by DCS may be related to
the reduction in the cell surface charge, signified by the increased CyC binding. As
observed in figure 2B, for A8799 there were also significant differences regarding CyC
binding in the presence of CFZ (1.21-fold increase) and FOM (1.09-fold increase), which
might be strain-dependent. Also, since FOM inhibits the uridine diphosphate (UDP)-Nacetylglucosamine enolpyruval transferase, these results stress the concept that reduction
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in the envelope charge is not specific to the mechanism of action of either DCS or the
beta-lactams. They also suggest that mechanisms additional to surface charge changes are
likely to be involved into synergism between CWA and daptomycin. Finally, our results
highlight the importance of the bacterial inoculum for daptomycin efficacy and the
difficulties to reach its targets in high bacterial density (17-19). This study has some
limitations. Given the profound see-saw effect observed with the beta-lactams, their
concentrations used against the DNS isolate were lower than those clinically achievable.
The potential neurotoxicity and contraindication of DCS in severe renal impairment could
severely limit its clinical use in treating severe MRSA infections. Nonetheless, this study
does suggest a way of overcoming MRSA daptomycin resistance and opens the door to
further research, based on reducing cell wall D-alanine composition, by inhibiting alanine
racemase or other steps in cell wall alanylation.
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Table 1: Daptomycin and cell wall agents’ minimum inhibitory concentrations (MIC) of a
MRSA isogenic pair of strains

MIC (µg/mL) (*)

Daptomycin

Vancomycin

Ampicillin

Oxacillin

Cefazolin

Imipenem

Fosfomycin

D-cycloserine

A8796

0.5

1

16

512

128

64

2

32

A8799

2

2

6

0.38

32

0.094

1

32

(*) MICs were determined two times. It was not detected significant increase in MIC at 48 hours with respect to that read at 24 hours,
for any of the antibiotics tested.

